Aprea Therapeutics Profit Margin

Aprea Therapeutics (APRE) currently reports a profit margin of -368812.14% as of June 2026. That compares with -4275.67% in the prior-year period — down 8525.8% year over year. That is below the Healthcare sector average of 10.58%. Use the charts on this page to explore Aprea Therapeutics's profit margin history and peer comparisons.

Aprea Therapeutics's profit margin decreased from -4275.67% to -368812.14% — a 8525.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aprea Therapeutics's profit margin of -368812.14% is lower than the Healthcare sector average of 10.58%. That is roughly 3485882.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Aprea Therapeutics's current -368812.14% should be judged against Healthcare norms (sector average: 10.58%) and against APRE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -368812.14%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 10.58%. From there, open related valuation or income-statement pages for Aprea Therapeutics, and consider following APRE for alerts when major investors trade the stock.